In Memory of Mike Watson

We are so very sad to announce that Mike Watson unexpectedly passed away on Saturday 27 August 2022.
September 2022

Mike was a fundamental part of the formation and success of our companies. He was Executive Chairman at VaxEquity, and co-founder and CEO of MEVOX.

Over his long and distinguished career, working in the UK, France, and the USA, he made a significant impact on global vaccine R&D, clinical development, vaccine introduction and vaccination policy for diseases including HPV, polio, and influenza. He also thought beyond vaccines, exploring how novel technologies and platforms such as mRNA could be used therapeutically. His thinking and work had a significant impact on global public health.

We are privileged to have worked alongside such an empathic, enthusiastic, and exceptional person. We will continue Mike’s inspiring work to improve human health all around the world.

Media contacts

Kerri Leach (VaxEquity)

Katja Stout (Scius Communications)

Daniel Gooch (Scius Communications)

About VaxEquity

VaxEquity is a UK biotechnology company developing next generation self-amplifying RNA and mRNA therapeutics and vaccines. Our proprietary RNA platform is designed to modulate the innate immune response to enable higher and longer protein expression allowing lower doses and expanding the potential of RNA for therapeutics as well as vaccines.

VaxEquity was founded in 2020 by Imperial College London’s Professor Robin Shattock, and specialist life sciences investor Morningside, and is led by a world class team who are RNA pioneers. The Company is based in Cambridge, UK, and is collaborating with AstraZeneca to progress its platform across multiple disease areas.

To learn more about VaxEquity please visit and follow our LinkedIn.

Get in touch

Thank you for your message

We have recieved your message and will get back to your shortly.